These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Immunological effects of thalidomide and its chemical and functional analogs. Dredge K; Marriott JB; Dalgleish AG Crit Rev Immunol; 2002; 22(5-6):425-37. PubMed ID: 12803319 [TBL] [Abstract][Full Text] [Related]
4. [Thalidomide: new uses for an old drug]. Wu KL; Sonneveld P Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1438-41. PubMed ID: 12190008 [TBL] [Abstract][Full Text] [Related]
5. [The revival of thalidomide: an old drug with new indications]. Laffitte E Rev Prat; 2006 Nov; 56(18):1977-83. PubMed ID: 17274497 [TBL] [Abstract][Full Text] [Related]
6. Thalidomide: current and potential clinical applications. Calabrese L; Fleischer AB Am J Med; 2000 Apr; 108(6):487-95. PubMed ID: 10781782 [TBL] [Abstract][Full Text] [Related]
8. Thalidomid: current role in the treatment of non-plasma cell malignancies. Kumar S; Witzig TE; Rajkumar SV J Clin Oncol; 2004 Jun; 22(12):2477-88. PubMed ID: 15197211 [TBL] [Abstract][Full Text] [Related]
9. Thalidomide: dual benefits in palliative medicine and oncology. Davis MP; Dickerson ED Am J Hosp Palliat Care; 2001; 18(5):347-51. PubMed ID: 11565189 [TBL] [Abstract][Full Text] [Related]
10. Thalidomide: from teratogen to anti-angiogenic. Grover JK; Vats K Indian J Cancer; 2001 Mar; 38(1):22-32. PubMed ID: 14758882 [TBL] [Abstract][Full Text] [Related]
12. Thalidomide makes a comeback. Dodd-Butera T; Broderick M RN; 2003 May; 66(5):32-5; quiz 36. PubMed ID: 12778690 [No Abstract] [Full Text] [Related]
13. Dermatologic and nondermatologic uses of thalidomide. Nasca MR; Micali G; Cheigh NH; West LE; West DP Ann Pharmacother; 2003 Sep; 37(9):1307-20. PubMed ID: 12921515 [TBL] [Abstract][Full Text] [Related]
14. Adverse effects of thalidomide administration in patients with neoplastic diseases. Dimopoulos MA; Eleutherakis-Papaiakovou V Am J Med; 2004 Oct; 117(7):508-15. PubMed ID: 15464708 [TBL] [Abstract][Full Text] [Related]
15. [An old drug as a carcinostatic. The new career of thalidomide]. Holzgrabe U Pharm Unserer Zeit; 2007; 36(6):446-9. PubMed ID: 17957689 [TBL] [Abstract][Full Text] [Related]
16. Thalidomide in solid tumours: the resurrection of an old drug. Sleijfer S; Kruit WH; Stoter G Eur J Cancer; 2004 Nov; 40(16):2377-82. PubMed ID: 15519508 [TBL] [Abstract][Full Text] [Related]
17. [Thalidomide: new perspectives for its use as antiinflammatory, immunossupressive and antiangiogenic drug]. Borges Lde G; Frõehlich PE Rev Assoc Med Bras (1992); 2003; 49(1):96-102. PubMed ID: 12724820 [TBL] [Abstract][Full Text] [Related]
18. Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders. Ladizinski B; Shannon EJ; Sanchez MR; Levis WR J Drugs Dermatol; 2010 Jul; 9(7):814-26. PubMed ID: 20677538 [TBL] [Abstract][Full Text] [Related]
19. A review of thalidomide's history and current dermatological applications. Perri AJ; Hsu S Dermatol Online J; 2003 Aug; 9(3):5. PubMed ID: 12952752 [TBL] [Abstract][Full Text] [Related]